JPMorgan analyst Benjamin Rossi assumed coverage of Ardent Health (ARDT) with a Neutral rating and $20 price target The firm believes favorable trends across sales and expenses for managed care companies should allow for margin expansion in 2025, but considers the setup into 2026 to be more bearish, saying potential volume rollover and regulatory uncertainty following the November elections present an “imperfect storm” of payer mix headwinds and a negative overhang on go-forward sentiment for the hospitals.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health Partners Announces Strong Q3 2024 Results
- Ardent Health reports Q3 EPS 19c, consensus 30c
- Ardent Health lowers 2024 EPS view to $1.18-$1.32 from $1.23-$1.37
- BofA shakes up ratings of healthcare stocks following Trump win
- Five Below downgraded, Snowflake upgraded: Wall Street’s top analyst calls